Co-Diagnostics (NASDAQ:CODX) Given New $2.50 Price Target at HC Wainwright

Co-Diagnostics (NASDAQ:CODX) had its price target decreased by HC Wainwright from $3.00 to $2.50 in a report issued on Friday, Benzinga reports. HC Wainwright currently has a neutral rating on the stock.

Co-Diagnostics Stock Down 0.9 %

Shares of NASDAQ CODX traded down $0.01 during midday trading on Friday, reaching $1.06. 105,249 shares of the stock were exchanged, compared to its average volume of 67,095. The firm has a market cap of $32.41 million, a price-to-earnings ratio of -0.88 and a beta of -0.67. Co-Diagnostics has a twelve month low of $0.98 and a twelve month high of $2.55. The firm has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.19.

Institutional Investors Weigh In On Co-Diagnostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CODX. Vanguard Group Inc. raised its holdings in shares of Co-Diagnostics by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,871,914 shares of the company’s stock worth $11,568,000 after acquiring an additional 76,857 shares during the period. Renaissance Technologies LLC grew its position in shares of Co-Diagnostics by 3.1% during the third quarter. Renaissance Technologies LLC now owns 704,800 shares of the company’s stock worth $2,262,000 after buying an additional 21,300 shares in the last quarter. BlackRock Inc. grew its position in shares of Co-Diagnostics by 7.6% during the third quarter. BlackRock Inc. now owns 539,595 shares of the company’s stock worth $1,732,000 after buying an additional 37,953 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Co-Diagnostics by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 319,494 shares of the company’s stock valued at $805,000 after purchasing an additional 14,879 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Co-Diagnostics by 6.4% in the third quarter. Bank of New York Mellon Corp now owns 237,675 shares of the company’s stock valued at $762,000 after purchasing an additional 14,326 shares in the last quarter. Institutional investors and hedge funds own 14.59% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.